Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Assessing radiotherapy for men with newly diagnosed metastatic prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 446
Rating:

Dr Chris C. Parker - The Royal Marsden, London, UK

Dr Chris C. Parker speaks with ecancer at ESMO 2018 in Munich about survival results from STAMPEDE, assessing radiotherapy for men with newly diagnosed metastatic prostate cancer.

He outlines the response rates for patients which ultimately were not different to a statistically significant degree, noting the better results in men with lower metastatic burden whose PFS improved, as did the percentage surviving to 3 years and beyond.

For more on this data, watch his presentation of the trial results at a conference session.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

War on Cancer 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation